<PAGE>
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
August 18, 1995
XYTRONYX, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
--------------------------------
(State or other jurisdiction of incorporation
0-14838 36-3258753
-------------------------- ------------------------------------
(Commissioner File Number) (IRS Employer Identification Number)
6555 Nancy Ridge Drive
Suite 200
San Diego, California 92121
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number,
including area code (619) 546-1114
--------------
<PAGE>
Item 5. Other Events.
The News Releases dated August 11, 1995, filed as Exhibit 99.38 and
99.39 hereto, are hereby incorporated into this Report by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits. The following exhibits accompany this Report:
--------
Exhibit
Number Exhibit Description
------ -------------------
99.38 News Release dated August 11, 1995
99.39 News Release dated August 11, 1995
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XYTRONYX, INC.
By: /s/ DALE SANDER
-----------------------------
Dale Sander
Chief Financial Officer
Date: August 18, 1995
<PAGE>
Index to Exhibits
-----------------
Sequentially
Exhibit Number Description of Exhibit Numbered Page
-------------- ---------------------- -------------
99.38 News Release dated August 11, 1995 4, 5
99.39 News Release dated August 11, 1995 6
<PAGE>
LETTERHEAD OF XYTRONYX, INC.
FOR IMMEDIATE RELEASE
CONTACT: Dale A. Sander, CFO
(619) 546-1114
________________________________________________________________________________
XYTRONYX, INC. REPORTS FISCAL 1996 FIRST QUARTER RESULTS
SAN DIEGO, CA, AUGUST 11, 1995 -- Xytronyx, Inc. (AMEX: XYX) today announced
results for the fiscal first quarter ended June 30, 1995.
Revenues for the first quarter ended June 30, 1995 were $95,000 compared to
$955,000 for the same period of the prior year. Net loss for the quarter was
$708,000 or $0.13 per share, compared to a loss of $689,000 or $0.14 per share
for the first quarter of the prior year.
Prior year revenues included proceeds from an agreement with Coors Brewing
Company for the use of Xytronyx's Kephra(TM) reversible color change technology
in a summer 1994 promotion. No such revenues were earned in the current quarter.
Xytronyx, Inc. is engaged in the development and commercialization of products
based on biotechnological research primarily in the areas of medicine, dentistry
and veterinary medicine.
(table follows)
<PAGE>
XYTRONYX, INC. AND SUBSIDIARY (A Development Stage Company)
CONSOLIDATED FINANCIAL DATA (unaudited)
<TABLE>
<CAPTION>
Three Months Ended
June 30
--------------------------
1995 1994
-----------------------------------------------------------------
<S> <C> <C>
REVENUES
Product sales $ - $ 599,729
License fees and royalties - 220,000
Contract research 40,000 99,151
Option agreements - -
Interest and other 54,901 36,319
-----------------------------------------------------------------
Total revenues 94,901 955,199
-----------------------------------------------------------------
COSTS AND EXPENSES
Cost of product sales 31,017 299,253
Product development 257,670 655,463
General and administrative 415,855 441,131
Business development
and marketing 94,416 229,986
Interest and other 3,895 17,907
-----------------------------------------------------------------
Total costs and expenses 802,853 1,643,740
-----------------------------------------------------------------
Net loss $ (707,952) $ (688,541)
-----------------------------------------------------------------
Net Loss Per Share
of Common Stock ($0.13) ($0.14)
-----------------------------------------------------------------
Weighted Average
Shares Outstanding 5,263,029 4,906,436
-----------------------------------------------------------------
Balance Sheet Data as of
June 30, 1995 March 31, 1995
------------------------------
Cash, cash equivalents and
short-term investments $992,647 $1,820,078
Total assets 1,845,328 2,304,937
Long-term liabilities 11,895 24,353
Stockholders' equity 1,175,857 1,883,809
</TABLE>
<PAGE>
LETTERHEAD FOR XYTRONYX, INC.
FOR IMMEDIATE RELEASE
CONTACT: Dale A. Sander, Chief Financial Officer
Larry Bymaster, Chief Executive Officer
(619) 546-1114
________________________________________________________________________________
XYTRONYX, INC. EXTENDS STANDSTILL AGREEMENT REGARDING THE
XYTRONYX PERIODONTAL TISSUE MONITOR
SAN DIEGO, CA, AUGUST 11, 1995 -- Xytronyx, Inc. (AMEX: XYX) announced that it
has agreed to extend for an additional five weeks the "Standstill Agreement"
with a company based in the United States. As previously announced on July 7,
1995, Xytronyx will not enter into any agreements to market the Xytronyx
Periodontal Tissue Monitor during the period of the Standstill Agreement.
"The extension gives Xytronyx and the company the time to finalize our
respective evaluations of a possible marketing agreement between our two
companies," said Larry Bymaster, Chairman and CEO of Xytronyx. "We are
continuing to evaluate other potential marketing partners based in both the
United States and Europe."
The Periodontal Tissue Monitor is designed to assist with the diagnosis and to
monitor the effectiveness of treating periodontitis, a common form of gum
disease and the leading cause of tooth loss in adults. The Periodontal Tissue
Monitor has been approved for sale in certain Western European Countries,
Canada, and the People's Republic of China. Clinical trials are currently being
held in the United States, and Xytronyx expects after completion of the trials
to file with the FDA for approval to market the product in the United States.
